Cost-effectiveness of a structured medication review approach for multimorbid older adults: Within-trial analysis of the OPERAM study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
09
2021
accepted:
01
03
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Inappropriate polypharmacy has been linked with adverse outcomes in older, multimorbid adults. OPERAM is a European cluster-randomized trial aimed at testing the effect of a structured pharmacotherapy optimization intervention on preventable drug-related hospital admissions in multimorbid adults with polypharmacy aged 70 years or older. Clinical results of the trial showed a pattern of reduced drug-related hospital admissions, but without statistical significance. In this study we assessed the cost-effectiveness of the pharmacotherapy optimisation intervention. We performed a pre-planned within-trial cost-effectiveness analysis (CEA) of the OPERAM intervention, from a healthcare system perspective. All data were collected within the trial apart from unit costs. QALYs were computed by applying the crosswalk German valuation algorithm to EQ-5D-5L-based quality of life data. Considering the clustered structure of the data and between-country heterogeneity, we applied Generalized Structural Equation Models (GSEMs) on a multiple imputed sample to estimate costs and QALYs. We also performed analyses by country and subgroup analyses by patient and morbidity characteristics. Trial-wide, the intervention was numerically dominant, with a potential cost-saving of CHF 3'588 (95% confidence interval (CI): -7'716; 540) and gain of 0.025 QALYs (CI: -0.002; 0.052) per patient. Robustness analyses confirmed the validity of the GSEM model. Subgroup analyses suggested stronger effects in people at higher risk. We observed a pattern towards dominance, potentially resulting from an accumulation of multiple small positive intervention effects. Our methodological approaches may inform other CEAs of multi-country, cluster-randomized trials facing presence of missing values and heterogeneity between centres/countries.
Sections du résumé
BACKGROUND
Inappropriate polypharmacy has been linked with adverse outcomes in older, multimorbid adults. OPERAM is a European cluster-randomized trial aimed at testing the effect of a structured pharmacotherapy optimization intervention on preventable drug-related hospital admissions in multimorbid adults with polypharmacy aged 70 years or older. Clinical results of the trial showed a pattern of reduced drug-related hospital admissions, but without statistical significance. In this study we assessed the cost-effectiveness of the pharmacotherapy optimisation intervention.
METHODS
We performed a pre-planned within-trial cost-effectiveness analysis (CEA) of the OPERAM intervention, from a healthcare system perspective. All data were collected within the trial apart from unit costs. QALYs were computed by applying the crosswalk German valuation algorithm to EQ-5D-5L-based quality of life data. Considering the clustered structure of the data and between-country heterogeneity, we applied Generalized Structural Equation Models (GSEMs) on a multiple imputed sample to estimate costs and QALYs. We also performed analyses by country and subgroup analyses by patient and morbidity characteristics.
RESULTS
Trial-wide, the intervention was numerically dominant, with a potential cost-saving of CHF 3'588 (95% confidence interval (CI): -7'716; 540) and gain of 0.025 QALYs (CI: -0.002; 0.052) per patient. Robustness analyses confirmed the validity of the GSEM model. Subgroup analyses suggested stronger effects in people at higher risk.
CONCLUSION
We observed a pattern towards dominance, potentially resulting from an accumulation of multiple small positive intervention effects. Our methodological approaches may inform other CEAs of multi-country, cluster-randomized trials facing presence of missing values and heterogeneity between centres/countries.
Identifiants
pubmed: 35404990
doi: 10.1371/journal.pone.0265507
pii: PONE-D-21-29278
pmc: PMC9000111
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265507Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Respir J. 2010 Mar;35(3):532-9
pubmed: 19717476
Int J Environ Res Public Health. 2019 Aug 16;16(16):
pubmed: 31426382
Value Health. 2009 Nov-Dec;12(8):1194-200
pubmed: 19695009
BMJ. 2021 Jul 13;374:n1585
pubmed: 34257088
Diabetologia. 1999 Nov;42(11):1293-301
pubmed: 10550412
Health Econ. 2005 May;14(5):471-85
pubmed: 15386662
BMJ Open. 2019 Jan 30;9(1):e021832
pubmed: 30705233
BMJ. 2004 Jul 3;329(7456):15-9
pubmed: 15231615
Br J Gen Pract. 2020 Dec 28;71(702):e39-e46
pubmed: 33257463
Pharmacoeconomics. 2018 Aug;36(8):889-901
pubmed: 29679317
Health Qual Life Outcomes. 2014 May 16;12:74
pubmed: 24885017
PLoS One. 2017 Nov 9;12(11):e0187477
pubmed: 29121647
J Health Serv Res Policy. 1999 Apr;4(2):122-6
pubmed: 10387404
Value Health. 2015 Mar;18(2):161-72
pubmed: 25773551
Int J Technol Assess Health Care. 2017 Jan;33(4):494-503
pubmed: 29019297
Med Care. 2016 Oct;54(10):950-64
pubmed: 27367864
Health Econ. 1998 Sep;7(6):481-93
pubmed: 9809707
Qual Life Res. 2015 Jul;24(7):1775-84
pubmed: 25555837
Med Decis Making. 2010 Mar-Apr;30(2):163-75
pubmed: 19675321
Eur J Health Econ. 2020 Jul;21(5):717-728
pubmed: 32108274
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Health Qual Life Outcomes. 2015 Oct 21;13:171
pubmed: 26489956
Lancet Reg Health Eur. 2021 Jul 14;8:100165
pubmed: 34557854
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Cardiology. 1999;91(3):189-94
pubmed: 10516413
Pharmacoeconomics. 2006;24(11):1101-19
pubmed: 17067195
Health Qual Life Outcomes. 2018 Sep 15;16(1):186
pubmed: 30219061
J Clin Epidemiol. 2014 Jan;67(1):93-9
pubmed: 24075597
J Health Econ. 2006 Nov;25(6):1015-28
pubmed: 16540192
Arch Intern Med. 2009 May 11;169(9):894-900
pubmed: 19433702
Health Econ. 2007 Aug;16(8):815-26
pubmed: 17191271
Stat Med. 2003 Jun 30;22(12):1955-76
pubmed: 12802815
Value Health. 2019 Mar;22(3):267-275
pubmed: 30832964
Infection. 1995;23 Suppl 1:S21-4
pubmed: 7782111
Health Econ. 1999 Jun;8(4):323-33
pubmed: 10398525
J Eval Clin Pract. 2018 Apr;24(2):317-322
pubmed: 28776873
BMC Health Serv Res. 2020 Mar 17;20(1):220
pubmed: 32183810
Cochrane Database Syst Rev. 2016 Feb 12;2:CD009095
pubmed: 26866421
Qual Life Res. 2010 Oct;19(8):1145-54
pubmed: 20496167
BMJ Open. 2019 Jun 3;9(6):e026769
pubmed: 31164366